Which has the lower trailing P/E, BMRN or RGEN?

BMRN has the lower trailing P/E: BMRN trades at 144.15 and RGEN at 239.53. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or RGEN?

Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus RGEN at 9.08%.

Is BMRN or RGEN more profitable?

RGEN runs the higher net margin — BMRN at 2.14% versus RGEN at 5.29%.

How have BMRN and RGEN total returns compared?

Over the past 10 years, BMRN delivered -4.98% and RGEN delivered 20.13% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs Repligen Corporation (RGEN)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and Repligen Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$10.87B

$56.22HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RGEN

Repligen Corporation

$9.87B

$174.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BMRN vs RGEN

growth of $100 · dividends reinvested · last 10y

BMRN -33.8% (-4.0%/yr)RGEN +528.7% (+20.2%/yr)RGEN compounded faster over this window

Log scale — wide-divergence pair

BMRN RGEN

BMRN vs RGEN: by the numbers

•BMRN is the larger company ($10.87B vs $9.87B market cap).
•BMRN trades at the lower trailing earnings multiple (144.15 vs 239.53 P/E), one valuation lens rather than an overall verdict.
•RGEN converts more revenue to profit (5.29% vs 2.14% net margin).
•BMRN grew revenue faster over the past five years (12.19% vs 9.08% CAGR).

Metrics side by side

Valuation

Metric	BMRN	RGEN
P/E ratio	144.15	239.53
Forward P/E	N/A	84.92
P/S ratio	3.19	12.57
P/B ratio	1.72	4.67
EV / EBITDA	33.30	67.03
FCF yield	6.74%	1.12%

Profitability

Metric	BMRN	RGEN
Gross margin	75.55%	51.05%
Operating margin	16.56%	8.32%
Net margin	2.14%	5.29%
ROE	1.15%	1.97%
ROIC	1.40%	1.85%

Growth (annualized)

Metric	BMRN	RGEN
Revenue CAGR (5Y)	12.19%	9.08%
EPS CAGR (5Y)	-17.46%	-5.26%
FCF CAGR (5Y)	33.84%	22.49%
Total return CAGR (5Y)	-5.59%	-6.86%

Frequently asked

Which has the lower trailing P/E, BMRN or RGEN?: BMRN has the lower trailing P/E: BMRN trades at 144.15 and RGEN at 239.53. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or RGEN?: Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus RGEN at 9.08%.
Is BMRN or RGEN more profitable?: RGEN runs the higher net margin — BMRN at 2.14% versus RGEN at 5.29%.
How have BMRN and RGEN total returns compared?: Over the past 10 years, BMRN delivered -4.98% and RGEN delivered 20.13% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full RGEN analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio Repligen P/E ratio BioMarin Pharmaceutical ROE Repligen ROE BioMarin Pharmaceutical operating margin Repligen operating margin BioMarin Pharmaceutical revenue growth Repligen revenue growth BioMarin Pharmaceutical free cash flow Repligen free cash flow

BioMarin Pharmaceutical & Repligen appear in these rankings

Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.